A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia
-
- Michele Baccarani
- From the L. and A. Seràgnoli Institute of Hematology and Medical Oncology, S. Orsola Hospital, University of Bologna, Italy; Division of Hematology, Udine University Hospital, Italy; Division of Hematology, La Sapienza, Rome University, Italy; and Division of Internal Medicine, University of Turin at Orbassano, Italy.
-
- Gianantonio Rosti
- From the L. and A. Seràgnoli Institute of Hematology and Medical Oncology, S. Orsola Hospital, University of Bologna, Italy; Division of Hematology, Udine University Hospital, Italy; Division of Hematology, La Sapienza, Rome University, Italy; and Division of Internal Medicine, University of Turin at Orbassano, Italy.
-
- Antonio de Vivo
- From the L. and A. Seràgnoli Institute of Hematology and Medical Oncology, S. Orsola Hospital, University of Bologna, Italy; Division of Hematology, Udine University Hospital, Italy; Division of Hematology, La Sapienza, Rome University, Italy; and Division of Internal Medicine, University of Turin at Orbassano, Italy.
-
- Francesca Bonifazi
- From the L. and A. Seràgnoli Institute of Hematology and Medical Oncology, S. Orsola Hospital, University of Bologna, Italy; Division of Hematology, Udine University Hospital, Italy; Division of Hematology, La Sapienza, Rome University, Italy; and Division of Internal Medicine, University of Turin at Orbassano, Italy.
-
- Domenico Russo
- From the L. and A. Seràgnoli Institute of Hematology and Medical Oncology, S. Orsola Hospital, University of Bologna, Italy; Division of Hematology, Udine University Hospital, Italy; Division of Hematology, La Sapienza, Rome University, Italy; and Division of Internal Medicine, University of Turin at Orbassano, Italy.
-
- Giovanni Martinelli
- From the L. and A. Seràgnoli Institute of Hematology and Medical Oncology, S. Orsola Hospital, University of Bologna, Italy; Division of Hematology, Udine University Hospital, Italy; Division of Hematology, La Sapienza, Rome University, Italy; and Division of Internal Medicine, University of Turin at Orbassano, Italy.
-
- Nicoletta Testoni
- From the L. and A. Seràgnoli Institute of Hematology and Medical Oncology, S. Orsola Hospital, University of Bologna, Italy; Division of Hematology, Udine University Hospital, Italy; Division of Hematology, La Sapienza, Rome University, Italy; and Division of Internal Medicine, University of Turin at Orbassano, Italy.
-
- Marilina Amabile
- From the L. and A. Seràgnoli Institute of Hematology and Medical Oncology, S. Orsola Hospital, University of Bologna, Italy; Division of Hematology, Udine University Hospital, Italy; Division of Hematology, La Sapienza, Rome University, Italy; and Division of Internal Medicine, University of Turin at Orbassano, Italy.
-
- Mauro Fiacchini
- From the L. and A. Seràgnoli Institute of Hematology and Medical Oncology, S. Orsola Hospital, University of Bologna, Italy; Division of Hematology, Udine University Hospital, Italy; Division of Hematology, La Sapienza, Rome University, Italy; and Division of Internal Medicine, University of Turin at Orbassano, Italy.
-
- Enrico Montefusco
- From the L. and A. Seràgnoli Institute of Hematology and Medical Oncology, S. Orsola Hospital, University of Bologna, Italy; Division of Hematology, Udine University Hospital, Italy; Division of Hematology, La Sapienza, Rome University, Italy; and Division of Internal Medicine, University of Turin at Orbassano, Italy.
-
- Giuseppe Saglio
- From the L. and A. Seràgnoli Institute of Hematology and Medical Oncology, S. Orsola Hospital, University of Bologna, Italy; Division of Hematology, Udine University Hospital, Italy; Division of Hematology, La Sapienza, Rome University, Italy; and Division of Internal Medicine, University of Turin at Orbassano, Italy.
-
- Sante Tura
- From the L. and A. Seràgnoli Institute of Hematology and Medical Oncology, S. Orsola Hospital, University of Bologna, Italy; Division of Hematology, Udine University Hospital, Italy; Division of Hematology, La Sapienza, Rome University, Italy; and Division of Internal Medicine, University of Turin at Orbassano, Italy.
説明
<jats:p>Interferon-α (IFN-α) has significantly prolonged survival in chronic myeloid leukemia (CML), but some patients do not respond and many responses are not durable. To improve the results, IFN-α has been combined with other treatments, but so far only the association with low-dose arabinosyl cytosine (LDAC) has been shown to increase the response rate and to prolong survival. Here are reported the results of a study of 538 Philadelphia chromosome–positive CML patients who were assigned at random to treatment with IFN-α2a alone or in combination with LDAC. The scheduled dose of IFN-α2a was 56IU/m2/d. The scheduled dose of AC was 40 mg/d for the first 10 days of each month of treatment. The efficacy endpoints were a complete hematologic response rate at 6 months (62% in the IFN-α–plus–LDAC arm versus 55% in the IFN-α arm; P = .11), major cytogenetic response (MCgR) rate at 24 months (28% versus 18%; P = .003), and overall survival (5-year survival, 68% versus 65%; P = .77). Treatment did not affect overall survival within different prognostic risk groups: low, intermediate, or high. Also the duration of MCgR was identical. The results of this study confirm the results of a similar French study only for the response rate, not for survival, suggesting that the relationship between cytogenetic response and survival may be extremely variable and that a meta-analysis of these and other studies of IFN-α versus IFN-α plus LDAC is required to settle the issue of the role of LDAC in the treatment of CML.</jats:p>
収録刊行物
-
- Blood
-
Blood 99 (5), 1527-1535, 2002-03-01
American Society of Hematology